Glaxo Faces Another Antitrust Suit Over Relafen Patent
GlaxoSmithKline, which already has agreed to pay over $250 million to settle charges it broke antitrust law by trying to block generic competition for the arthritis drug Relafen, is facing accusations...To view the full article, register now.
Already a subscriber? Click here to view full article